nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ALB—multiple sclerosis	0.227	1	CbGaD
Tacrolimus—ALB—Prednisone—multiple sclerosis	0.0321	0.0968	CbGbCtD
Tacrolimus—ABCB1—Methylprednisolone—multiple sclerosis	0.0277	0.0836	CbGbCtD
Tacrolimus—CYP3A4—Fingolimod—multiple sclerosis	0.0258	0.0777	CbGbCtD
Tacrolimus—CYP3A7—Dexamethasone—multiple sclerosis	0.0215	0.0648	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0215	0.0648	CbGbCtD
Tacrolimus—ABCB1—Mitoxantrone—multiple sclerosis	0.0202	0.061	CbGbCtD
Tacrolimus—ABCB1—Betamethasone—multiple sclerosis	0.018	0.0544	CbGbCtD
Tacrolimus—ABCB1—Prednisolone—multiple sclerosis	0.0178	0.0536	CbGbCtD
Tacrolimus—ABCB1—Prednisone—multiple sclerosis	0.0168	0.0506	CbGbCtD
Tacrolimus—CYP3A4—Methylprednisolone—multiple sclerosis	0.0166	0.0501	CbGbCtD
Tacrolimus—CYP3A5—Dexamethasone—multiple sclerosis	0.0161	0.0486	CbGbCtD
Tacrolimus—ALB—Methotrexate—multiple sclerosis	0.0161	0.0486	CbGbCtD
Tacrolimus—CYP3A4—Triamcinolone—multiple sclerosis	0.0126	0.038	CbGbCtD
Tacrolimus—CYP3A4—Mitoxantrone—multiple sclerosis	0.0121	0.0365	CbGbCtD
Tacrolimus—CYP3A4—Betamethasone—multiple sclerosis	0.0108	0.0326	CbGbCtD
Tacrolimus—CYP3A4—Prednisolone—multiple sclerosis	0.0107	0.0321	CbGbCtD
Tacrolimus—ABCB1—Dexamethasone—multiple sclerosis	0.0105	0.0316	CbGbCtD
Tacrolimus—PPP3CA—pons—multiple sclerosis	0.0102	0.154	CbGeAlD
Tacrolimus—CYP3A4—Prednisone—multiple sclerosis	0.0101	0.0303	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—multiple sclerosis	0.00843	0.0254	CbGbCtD
Tacrolimus—MTOR—leg—multiple sclerosis	0.0072	0.108	CbGeAlD
Tacrolimus—CYP3A4—Dexamethasone—multiple sclerosis	0.00629	0.0189	CbGbCtD
Tacrolimus—ABCA5—retina—multiple sclerosis	0.00324	0.0489	CbGeAlD
Tacrolimus—ABCA5—medulla oblongata—multiple sclerosis	0.00235	0.0353	CbGeAlD
Tacrolimus—PPP3CA—brainstem—multiple sclerosis	0.00227	0.0342	CbGeAlD
Tacrolimus—PPP3CA—retina—multiple sclerosis	0.00219	0.033	CbGeAlD
Tacrolimus—ABCA5—midbrain—multiple sclerosis	0.00214	0.0323	CbGeAlD
Tacrolimus—ABCA5—spinal cord—multiple sclerosis	0.00209	0.0315	CbGeAlD
Tacrolimus—ABCA5—nervous system—multiple sclerosis	0.00176	0.0265	CbGeAlD
Tacrolimus—ABCA5—central nervous system—multiple sclerosis	0.0017	0.0255	CbGeAlD
Tacrolimus—MTOR—brainstem—multiple sclerosis	0.00168	0.0253	CbGeAlD
Tacrolimus—ABCA5—cerebellum—multiple sclerosis	0.00166	0.025	CbGeAlD
Tacrolimus—MTOR—retina—multiple sclerosis	0.00162	0.0244	CbGeAlD
Tacrolimus—PPP3CA—medulla oblongata—multiple sclerosis	0.00158	0.0239	CbGeAlD
Tacrolimus—FKBP1A—retina—multiple sclerosis	0.00146	0.0219	CbGeAlD
Tacrolimus—PPP3CA—midbrain—multiple sclerosis	0.00145	0.0218	CbGeAlD
Tacrolimus—PPP3CA—spinal cord—multiple sclerosis	0.00141	0.0213	CbGeAlD
Tacrolimus—ABCA5—brain—multiple sclerosis	0.00135	0.0203	CbGeAlD
Tacrolimus—PPP3CA—nervous system—multiple sclerosis	0.00119	0.0179	CbGeAlD
Tacrolimus—PPP3CA—central nervous system—multiple sclerosis	0.00115	0.0173	CbGeAlD
Tacrolimus—PPP3CA—cerebellum—multiple sclerosis	0.00112	0.0169	CbGeAlD
Tacrolimus—FKBP1A—medulla oblongata—multiple sclerosis	0.00105	0.0158	CbGeAlD
Tacrolimus—MTOR—spinal cord—multiple sclerosis	0.00104	0.0157	CbGeAlD
Tacrolimus—FKBP1A—midbrain—multiple sclerosis	0.000962	0.0145	CbGeAlD
Tacrolimus—FKBP1A—spinal cord—multiple sclerosis	0.000939	0.0141	CbGeAlD
Tacrolimus—PPP3CA—brain—multiple sclerosis	0.00091	0.0137	CbGeAlD
Tacrolimus—MTOR—nervous system—multiple sclerosis	0.000879	0.0132	CbGeAlD
Tacrolimus—MTOR—central nervous system—multiple sclerosis	0.000846	0.0127	CbGeAlD
Tacrolimus—MTOR—cerebellum—multiple sclerosis	0.000827	0.0125	CbGeAlD
Tacrolimus—FKBP1A—nervous system—multiple sclerosis	0.000791	0.0119	CbGeAlD
Tacrolimus—FKBP1A—central nervous system—multiple sclerosis	0.000761	0.0115	CbGeAlD
Tacrolimus—FKBP1A—cerebellum—multiple sclerosis	0.000744	0.0112	CbGeAlD
Tacrolimus—ORM1—spinal cord—multiple sclerosis	0.000735	0.0111	CbGeAlD
Tacrolimus—MTOR—brain—multiple sclerosis	0.000672	0.0101	CbGeAlD
Tacrolimus—ORM1—nervous system—multiple sclerosis	0.000619	0.00932	CbGeAlD
Tacrolimus—FKBP1A—brain—multiple sclerosis	0.000604	0.0091	CbGeAlD
Tacrolimus—ORM1—central nervous system—multiple sclerosis	0.000596	0.00898	CbGeAlD
Tacrolimus—ALB—brain—multiple sclerosis	0.000415	0.00625	CbGeAlD
Tacrolimus—ABCB1—retina—multiple sclerosis	0.000337	0.00507	CbGeAlD
Tacrolimus—CYP3A4—nervous system—multiple sclerosis	0.000258	0.00389	CbGeAlD
Tacrolimus—CYP3A4—central nervous system—multiple sclerosis	0.000249	0.00375	CbGeAlD
Tacrolimus—ABCB1—medulla oblongata—multiple sclerosis	0.000243	0.00367	CbGeAlD
Tacrolimus—ABCB1—midbrain—multiple sclerosis	0.000223	0.00335	CbGeAlD
Tacrolimus—ABCB1—spinal cord—multiple sclerosis	0.000217	0.00327	CbGeAlD
Tacrolimus—ABCB1—nervous system—multiple sclerosis	0.000183	0.00275	CbGeAlD
Tacrolimus—ABCB1—central nervous system—multiple sclerosis	0.000176	0.00265	CbGeAlD
Tacrolimus—ABCB1—cerebellum—multiple sclerosis	0.000172	0.00259	CbGeAlD
Tacrolimus—ABCB1—brain—multiple sclerosis	0.00014	0.00211	CbGeAlD
Tacrolimus—Tachycardia—Methylprednisolone—multiple sclerosis	5.63e-05	0.000211	CcSEcCtD
Tacrolimus—Skin disorder—Methylprednisolone—multiple sclerosis	5.6e-05	0.00021	CcSEcCtD
Tacrolimus—Erythema—Prednisone—multiple sclerosis	5.6e-05	0.00021	CcSEcCtD
Tacrolimus—Malnutrition—Prednisone—multiple sclerosis	5.6e-05	0.00021	CcSEcCtD
Tacrolimus—Hyperhidrosis—Triamcinolone—multiple sclerosis	5.59e-05	0.00021	CcSEcCtD
Tacrolimus—Agranulocytosis—Methotrexate—multiple sclerosis	5.59e-05	0.00021	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methylprednisolone—multiple sclerosis	5.58e-05	0.000209	CcSEcCtD
Tacrolimus—Convulsion—Dexamethasone—multiple sclerosis	5.57e-05	0.000209	CcSEcCtD
Tacrolimus—Convulsion—Betamethasone—multiple sclerosis	5.57e-05	0.000209	CcSEcCtD
Tacrolimus—Hypertension—Betamethasone—multiple sclerosis	5.55e-05	0.000208	CcSEcCtD
Tacrolimus—Hypertension—Dexamethasone—multiple sclerosis	5.55e-05	0.000208	CcSEcCtD
Tacrolimus—Asthenia—Mitoxantrone—multiple sclerosis	5.5e-05	0.000206	CcSEcCtD
Tacrolimus—Myalgia—Betamethasone—multiple sclerosis	5.47e-05	0.000205	CcSEcCtD
Tacrolimus—Myalgia—Dexamethasone—multiple sclerosis	5.47e-05	0.000205	CcSEcCtD
Tacrolimus—Anxiety—Betamethasone—multiple sclerosis	5.45e-05	0.000205	CcSEcCtD
Tacrolimus—Anxiety—Dexamethasone—multiple sclerosis	5.45e-05	0.000205	CcSEcCtD
Tacrolimus—Discomfort—Dexamethasone—multiple sclerosis	5.41e-05	0.000203	CcSEcCtD
Tacrolimus—Discomfort—Betamethasone—multiple sclerosis	5.41e-05	0.000203	CcSEcCtD
Tacrolimus—Haemoglobin—Methotrexate—multiple sclerosis	5.4e-05	0.000203	CcSEcCtD
Tacrolimus—Hypotension—Methylprednisolone—multiple sclerosis	5.39e-05	0.000202	CcSEcCtD
Tacrolimus—Pain—Prednisolone—multiple sclerosis	5.38e-05	0.000202	CcSEcCtD
Tacrolimus—Hepatitis—Methotrexate—multiple sclerosis	5.37e-05	0.000202	CcSEcCtD
Tacrolimus—Haemorrhage—Methotrexate—multiple sclerosis	5.37e-05	0.000202	CcSEcCtD
Tacrolimus—Pharyngitis—Methotrexate—multiple sclerosis	5.33e-05	0.0002	CcSEcCtD
Tacrolimus—Urinary tract disorder—Methotrexate—multiple sclerosis	5.31e-05	0.000199	CcSEcCtD
Tacrolimus—Vision blurred—Prednisone—multiple sclerosis	5.27e-05	0.000198	CcSEcCtD
Tacrolimus—Urethral disorder—Methotrexate—multiple sclerosis	5.27e-05	0.000198	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	5.27e-05	0.000198	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	5.25e-05	0.000197	CcSEcCtD
Tacrolimus—Anaphylactic shock—Betamethasone—multiple sclerosis	5.24e-05	0.000197	CcSEcCtD
Tacrolimus—Anaphylactic shock—Dexamethasone—multiple sclerosis	5.24e-05	0.000197	CcSEcCtD
Tacrolimus—Oedema—Dexamethasone—multiple sclerosis	5.24e-05	0.000197	CcSEcCtD
Tacrolimus—Oedema—Betamethasone—multiple sclerosis	5.24e-05	0.000197	CcSEcCtD
Tacrolimus—Diarrhoea—Mitoxantrone—multiple sclerosis	5.24e-05	0.000197	CcSEcCtD
Tacrolimus—Insomnia—Triamcinolone—multiple sclerosis	5.23e-05	0.000196	CcSEcCtD
Tacrolimus—Insomnia—Methylprednisolone—multiple sclerosis	5.22e-05	0.000196	CcSEcCtD
Tacrolimus—Infection—Dexamethasone—multiple sclerosis	5.21e-05	0.000196	CcSEcCtD
Tacrolimus—Infection—Betamethasone—multiple sclerosis	5.21e-05	0.000196	CcSEcCtD
Tacrolimus—Ill-defined disorder—Prednisone—multiple sclerosis	5.19e-05	0.000195	CcSEcCtD
Tacrolimus—Paraesthesia—Triamcinolone—multiple sclerosis	5.19e-05	0.000195	CcSEcCtD
Tacrolimus—Feeling abnormal—Prednisolone—multiple sclerosis	5.18e-05	0.000195	CcSEcCtD
Tacrolimus—Paraesthesia—Methylprednisolone—multiple sclerosis	5.18e-05	0.000194	CcSEcCtD
Tacrolimus—Visual impairment—Methotrexate—multiple sclerosis	5.18e-05	0.000194	CcSEcCtD
Tacrolimus—Anaemia—Prednisone—multiple sclerosis	5.17e-05	0.000194	CcSEcCtD
Tacrolimus—Shock—Dexamethasone—multiple sclerosis	5.16e-05	0.000194	CcSEcCtD
Tacrolimus—Shock—Betamethasone—multiple sclerosis	5.16e-05	0.000194	CcSEcCtD
Tacrolimus—Dyspnoea—Triamcinolone—multiple sclerosis	5.15e-05	0.000194	CcSEcCtD
Tacrolimus—Nervous system disorder—Dexamethasone—multiple sclerosis	5.14e-05	0.000193	CcSEcCtD
Tacrolimus—Nervous system disorder—Betamethasone—multiple sclerosis	5.14e-05	0.000193	CcSEcCtD
Tacrolimus—Agitation—Prednisone—multiple sclerosis	5.14e-05	0.000193	CcSEcCtD
Tacrolimus—Thrombocytopenia—Dexamethasone—multiple sclerosis	5.14e-05	0.000193	CcSEcCtD
Tacrolimus—Thrombocytopenia—Betamethasone—multiple sclerosis	5.14e-05	0.000193	CcSEcCtD
Tacrolimus—Tachycardia—Betamethasone—multiple sclerosis	5.12e-05	0.000192	CcSEcCtD
Tacrolimus—Tachycardia—Dexamethasone—multiple sclerosis	5.12e-05	0.000192	CcSEcCtD
Tacrolimus—Dyspepsia—Triamcinolone—multiple sclerosis	5.09e-05	0.000191	CcSEcCtD
Tacrolimus—Erythema multiforme—Methotrexate—multiple sclerosis	5.08e-05	0.000191	CcSEcCtD
Tacrolimus—Dyspepsia—Methylprednisolone—multiple sclerosis	5.08e-05	0.000191	CcSEcCtD
Tacrolimus—Hyperhidrosis—Dexamethasone—multiple sclerosis	5.07e-05	0.00019	CcSEcCtD
Tacrolimus—Hyperhidrosis—Betamethasone—multiple sclerosis	5.07e-05	0.00019	CcSEcCtD
Tacrolimus—Malaise—Prednisone—multiple sclerosis	5.05e-05	0.00019	CcSEcCtD
Tacrolimus—Vertigo—Prednisone—multiple sclerosis	5.03e-05	0.000189	CcSEcCtD
Tacrolimus—Eye disorder—Methotrexate—multiple sclerosis	5.02e-05	0.000189	CcSEcCtD
Tacrolimus—Syncope—Prednisone—multiple sclerosis	5.02e-05	0.000188	CcSEcCtD
Tacrolimus—Tinnitus—Methotrexate—multiple sclerosis	5.01e-05	0.000188	CcSEcCtD
Tacrolimus—Anorexia—Dexamethasone—multiple sclerosis	5e-05	0.000188	CcSEcCtD
Tacrolimus—Anorexia—Betamethasone—multiple sclerosis	5e-05	0.000188	CcSEcCtD
Tacrolimus—Urticaria—Prednisolone—multiple sclerosis	4.99e-05	0.000188	CcSEcCtD
Tacrolimus—Cardiac disorder—Methotrexate—multiple sclerosis	4.99e-05	0.000187	CcSEcCtD
Tacrolimus—Fatigue—Triamcinolone—multiple sclerosis	4.98e-05	0.000187	CcSEcCtD
Tacrolimus—Fatigue—Methylprednisolone—multiple sclerosis	4.97e-05	0.000187	CcSEcCtD
Tacrolimus—Pain—Triamcinolone—multiple sclerosis	4.94e-05	0.000186	CcSEcCtD
Tacrolimus—Loss of consciousness—Prednisone—multiple sclerosis	4.92e-05	0.000185	CcSEcCtD
Tacrolimus—Hypotension—Dexamethasone—multiple sclerosis	4.9e-05	0.000184	CcSEcCtD
Tacrolimus—Hypotension—Betamethasone—multiple sclerosis	4.9e-05	0.000184	CcSEcCtD
Tacrolimus—Angiopathy—Methotrexate—multiple sclerosis	4.87e-05	0.000183	CcSEcCtD
Tacrolimus—Vomiting—Mitoxantrone—multiple sclerosis	4.87e-05	0.000183	CcSEcCtD
Tacrolimus—Immune system disorder—Methotrexate—multiple sclerosis	4.85e-05	0.000182	CcSEcCtD
Tacrolimus—Convulsion—Prednisone—multiple sclerosis	4.85e-05	0.000182	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—multiple sclerosis	4.84e-05	0.000182	CcSEcCtD
Tacrolimus—Hypertension—Prednisone—multiple sclerosis	4.83e-05	0.000181	CcSEcCtD
Tacrolimus—Rash—Mitoxantrone—multiple sclerosis	4.83e-05	0.000181	CcSEcCtD
Tacrolimus—Dermatitis—Mitoxantrone—multiple sclerosis	4.83e-05	0.000181	CcSEcCtD
Tacrolimus—Chills—Methotrexate—multiple sclerosis	4.82e-05	0.000181	CcSEcCtD
Tacrolimus—Headache—Mitoxantrone—multiple sclerosis	4.8e-05	0.00018	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	4.78e-05	0.000179	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	4.78e-05	0.000179	CcSEcCtD
Tacrolimus—Myalgia—Prednisone—multiple sclerosis	4.76e-05	0.000179	CcSEcCtD
Tacrolimus—Arthralgia—Prednisone—multiple sclerosis	4.76e-05	0.000179	CcSEcCtD
Tacrolimus—Feeling abnormal—Triamcinolone—multiple sclerosis	4.76e-05	0.000179	CcSEcCtD
Tacrolimus—Feeling abnormal—Methylprednisolone—multiple sclerosis	4.75e-05	0.000178	CcSEcCtD
Tacrolimus—Anxiety—Prednisone—multiple sclerosis	4.75e-05	0.000178	CcSEcCtD
Tacrolimus—Alopecia—Methotrexate—multiple sclerosis	4.75e-05	0.000178	CcSEcCtD
Tacrolimus—Insomnia—Betamethasone—multiple sclerosis	4.74e-05	0.000178	CcSEcCtD
Tacrolimus—Insomnia—Dexamethasone—multiple sclerosis	4.74e-05	0.000178	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	4.73e-05	0.000178	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	4.72e-05	0.000177	CcSEcCtD
Tacrolimus—Paraesthesia—Betamethasone—multiple sclerosis	4.71e-05	0.000177	CcSEcCtD
Tacrolimus—Paraesthesia—Dexamethasone—multiple sclerosis	4.71e-05	0.000177	CcSEcCtD
Tacrolimus—Discomfort—Prednisone—multiple sclerosis	4.71e-05	0.000177	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—multiple sclerosis	4.71e-05	0.000177	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—multiple sclerosis	4.68e-05	0.000176	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—multiple sclerosis	4.68e-05	0.000176	CcSEcCtD
Tacrolimus—Hypersensitivity—Prednisolone—multiple sclerosis	4.63e-05	0.000174	CcSEcCtD
Tacrolimus—Dyspepsia—Dexamethasone—multiple sclerosis	4.62e-05	0.000173	CcSEcCtD
Tacrolimus—Dyspepsia—Betamethasone—multiple sclerosis	4.62e-05	0.000173	CcSEcCtD
Tacrolimus—Urticaria—Triamcinolone—multiple sclerosis	4.59e-05	0.000172	CcSEcCtD
Tacrolimus—Urticaria—Methylprednisolone—multiple sclerosis	4.58e-05	0.000172	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—multiple sclerosis	4.58e-05	0.000172	CcSEcCtD
Tacrolimus—Body temperature increased—Triamcinolone—multiple sclerosis	4.57e-05	0.000172	CcSEcCtD
Tacrolimus—Oedema—Prednisone—multiple sclerosis	4.57e-05	0.000172	CcSEcCtD
Tacrolimus—Anaphylactic shock—Prednisone—multiple sclerosis	4.57e-05	0.000172	CcSEcCtD
Tacrolimus—Abdominal pain—Methylprednisolone—multiple sclerosis	4.56e-05	0.000171	CcSEcCtD
Tacrolimus—Decreased appetite—Dexamethasone—multiple sclerosis	4.56e-05	0.000171	CcSEcCtD
Tacrolimus—Decreased appetite—Betamethasone—multiple sclerosis	4.56e-05	0.000171	CcSEcCtD
Tacrolimus—Nausea—Mitoxantrone—multiple sclerosis	4.55e-05	0.000171	CcSEcCtD
Tacrolimus—Infection—Prednisone—multiple sclerosis	4.54e-05	0.00017	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Betamethasone—multiple sclerosis	4.53e-05	0.00017	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	4.53e-05	0.00017	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—multiple sclerosis	4.52e-05	0.00017	CcSEcCtD
Tacrolimus—Fatigue—Dexamethasone—multiple sclerosis	4.52e-05	0.00017	CcSEcCtD
Tacrolimus—Fatigue—Betamethasone—multiple sclerosis	4.52e-05	0.00017	CcSEcCtD
Tacrolimus—Shock—Prednisone—multiple sclerosis	4.49e-05	0.000169	CcSEcCtD
Tacrolimus—Pain—Dexamethasone—multiple sclerosis	4.49e-05	0.000168	CcSEcCtD
Tacrolimus—Pain—Betamethasone—multiple sclerosis	4.49e-05	0.000168	CcSEcCtD
Tacrolimus—Nervous system disorder—Prednisone—multiple sclerosis	4.48e-05	0.000168	CcSEcCtD
Tacrolimus—Tachycardia—Prednisone—multiple sclerosis	4.46e-05	0.000167	CcSEcCtD
Tacrolimus—Skin disorder—Prednisone—multiple sclerosis	4.44e-05	0.000167	CcSEcCtD
Tacrolimus—Hyperhidrosis—Prednisone—multiple sclerosis	4.42e-05	0.000166	CcSEcCtD
Tacrolimus—Vision blurred—Methotrexate—multiple sclerosis	4.41e-05	0.000166	CcSEcCtD
Tacrolimus—Anorexia—Prednisone—multiple sclerosis	4.35e-05	0.000164	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—multiple sclerosis	4.34e-05	0.000163	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—multiple sclerosis	4.32e-05	0.000162	CcSEcCtD
Tacrolimus—Feeling abnormal—Dexamethasone—multiple sclerosis	4.32e-05	0.000162	CcSEcCtD
Tacrolimus—Feeling abnormal—Betamethasone—multiple sclerosis	4.32e-05	0.000162	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Dexamethasone—multiple sclerosis	4.29e-05	0.000161	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Betamethasone—multiple sclerosis	4.29e-05	0.000161	CcSEcCtD
Tacrolimus—Hypersensitivity—Triamcinolone—multiple sclerosis	4.26e-05	0.00016	CcSEcCtD
Tacrolimus—Hypersensitivity—Methylprednisolone—multiple sclerosis	4.25e-05	0.00016	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—multiple sclerosis	4.22e-05	0.000158	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—multiple sclerosis	4.2e-05	0.000158	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—multiple sclerosis	4.19e-05	0.000157	CcSEcCtD
Tacrolimus—Urticaria—Betamethasone—multiple sclerosis	4.17e-05	0.000156	CcSEcCtD
Tacrolimus—Urticaria—Dexamethasone—multiple sclerosis	4.17e-05	0.000156	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Prednisone—multiple sclerosis	4.16e-05	0.000156	CcSEcCtD
Tacrolimus—Dizziness—Prednisolone—multiple sclerosis	4.16e-05	0.000156	CcSEcCtD
Tacrolimus—Asthenia—Triamcinolone—multiple sclerosis	4.15e-05	0.000156	CcSEcCtD
Tacrolimus—Abdominal pain—Dexamethasone—multiple sclerosis	4.15e-05	0.000156	CcSEcCtD
Tacrolimus—Body temperature increased—Dexamethasone—multiple sclerosis	4.15e-05	0.000156	CcSEcCtD
Tacrolimus—Body temperature increased—Betamethasone—multiple sclerosis	4.15e-05	0.000156	CcSEcCtD
Tacrolimus—Abdominal pain—Betamethasone—multiple sclerosis	4.15e-05	0.000156	CcSEcCtD
Tacrolimus—Asthenia—Methylprednisolone—multiple sclerosis	4.14e-05	0.000155	CcSEcCtD
Tacrolimus—Insomnia—Prednisone—multiple sclerosis	4.13e-05	0.000155	CcSEcCtD
Tacrolimus—Paraesthesia—Prednisone—multiple sclerosis	4.1e-05	0.000154	CcSEcCtD
Tacrolimus—Pruritus—Triamcinolone—multiple sclerosis	4.09e-05	0.000154	CcSEcCtD
Tacrolimus—Cough—Methotrexate—multiple sclerosis	4.08e-05	0.000153	CcSEcCtD
Tacrolimus—Pruritus—Methylprednisolone—multiple sclerosis	4.08e-05	0.000153	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—multiple sclerosis	4.05e-05	0.000152	CcSEcCtD
Tacrolimus—Dyspepsia—Prednisone—multiple sclerosis	4.02e-05	0.000151	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—multiple sclerosis	3.98e-05	0.00015	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—multiple sclerosis	3.98e-05	0.00015	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—multiple sclerosis	3.98e-05	0.00015	CcSEcCtD
Tacrolimus—Decreased appetite—Prednisone—multiple sclerosis	3.97e-05	0.000149	CcSEcCtD
Tacrolimus—Rash—Prednisolone—multiple sclerosis	3.96e-05	0.000149	CcSEcCtD
Tacrolimus—Dermatitis—Prednisolone—multiple sclerosis	3.96e-05	0.000149	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	3.95e-05	0.000149	CcSEcCtD
Tacrolimus—Diarrhoea—Methylprednisolone—multiple sclerosis	3.95e-05	0.000148	CcSEcCtD
Tacrolimus—Fatigue—Prednisone—multiple sclerosis	3.94e-05	0.000148	CcSEcCtD
Tacrolimus—Headache—Prednisolone—multiple sclerosis	3.94e-05	0.000148	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—multiple sclerosis	3.93e-05	0.000148	CcSEcCtD
Tacrolimus—Constipation—Prednisone—multiple sclerosis	3.91e-05	0.000147	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—multiple sclerosis	3.85e-05	0.000145	CcSEcCtD
Tacrolimus—Dizziness—Triamcinolone—multiple sclerosis	3.82e-05	0.000144	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—multiple sclerosis	3.82e-05	0.000143	CcSEcCtD
Tacrolimus—Dizziness—Methylprednisolone—multiple sclerosis	3.81e-05	0.000143	CcSEcCtD
Tacrolimus—Infection—Methotrexate—multiple sclerosis	3.79e-05	0.000142	CcSEcCtD
Tacrolimus—Feeling abnormal—Prednisone—multiple sclerosis	3.76e-05	0.000141	CcSEcCtD
Tacrolimus—Asthenia—Dexamethasone—multiple sclerosis	3.76e-05	0.000141	CcSEcCtD
Tacrolimus—Asthenia—Betamethasone—multiple sclerosis	3.76e-05	0.000141	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—multiple sclerosis	3.74e-05	0.000141	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—multiple sclerosis	3.74e-05	0.00014	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Prednisone—multiple sclerosis	3.73e-05	0.00014	CcSEcCtD
Tacrolimus—Nausea—Prednisolone—multiple sclerosis	3.73e-05	0.00014	CcSEcCtD
Tacrolimus—Pruritus—Dexamethasone—multiple sclerosis	3.71e-05	0.000139	CcSEcCtD
Tacrolimus—Pruritus—Betamethasone—multiple sclerosis	3.71e-05	0.000139	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—multiple sclerosis	3.71e-05	0.000139	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—multiple sclerosis	3.69e-05	0.000139	CcSEcCtD
Tacrolimus—Vomiting—Triamcinolone—multiple sclerosis	3.68e-05	0.000138	CcSEcCtD
Tacrolimus—Vomiting—Methylprednisolone—multiple sclerosis	3.67e-05	0.000138	CcSEcCtD
Tacrolimus—Rash—Triamcinolone—multiple sclerosis	3.64e-05	0.000137	CcSEcCtD
Tacrolimus—Dermatitis—Triamcinolone—multiple sclerosis	3.64e-05	0.000137	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—multiple sclerosis	3.64e-05	0.000137	CcSEcCtD
Tacrolimus—Rash—Methylprednisolone—multiple sclerosis	3.64e-05	0.000137	CcSEcCtD
Tacrolimus—Dermatitis—Methylprednisolone—multiple sclerosis	3.63e-05	0.000136	CcSEcCtD
Tacrolimus—Urticaria—Prednisone—multiple sclerosis	3.63e-05	0.000136	CcSEcCtD
Tacrolimus—Headache—Triamcinolone—multiple sclerosis	3.62e-05	0.000136	CcSEcCtD
Tacrolimus—Headache—Methylprednisolone—multiple sclerosis	3.61e-05	0.000136	CcSEcCtD
Tacrolimus—Abdominal pain—Prednisone—multiple sclerosis	3.61e-05	0.000136	CcSEcCtD
Tacrolimus—Body temperature increased—Prednisone—multiple sclerosis	3.61e-05	0.000136	CcSEcCtD
Tacrolimus—Diarrhoea—Dexamethasone—multiple sclerosis	3.59e-05	0.000135	CcSEcCtD
Tacrolimus—Diarrhoea—Betamethasone—multiple sclerosis	3.59e-05	0.000135	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—multiple sclerosis	3.57e-05	0.000134	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—CXCR3—multiple sclerosis	3.51e-05	0.000325	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SLC11A1—multiple sclerosis	3.49e-05	0.000323	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD40LG—multiple sclerosis	3.49e-05	0.000323	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	3.48e-05	0.000131	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—CD28—multiple sclerosis	3.47e-05	0.000322	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.47e-05	0.000321	CbGpPWpGaD
Tacrolimus—Dizziness—Dexamethasone—multiple sclerosis	3.47e-05	0.00013	CcSEcCtD
Tacrolimus—Dizziness—Betamethasone—multiple sclerosis	3.47e-05	0.00013	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—HLA-B—multiple sclerosis	3.45e-05	0.00032	CbGpPWpGaD
Tacrolimus—Insomnia—Methotrexate—multiple sclerosis	3.45e-05	0.00013	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—CD8A—multiple sclerosis	3.45e-05	0.000319	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—IL6—multiple sclerosis	3.44e-05	0.000319	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RGS1—multiple sclerosis	3.43e-05	0.000318	CbGpPWpGaD
Tacrolimus—Nausea—Triamcinolone—multiple sclerosis	3.43e-05	0.000129	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—multiple sclerosis	3.43e-05	0.000129	CcSEcCtD
Tacrolimus—Nausea—Methylprednisolone—multiple sclerosis	3.43e-05	0.000129	CcSEcCtD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	3.43e-05	0.000317	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCR2—multiple sclerosis	3.41e-05	0.000316	CbGpPWpGaD
Tacrolimus—Dyspnoea—Methotrexate—multiple sclerosis	3.4e-05	0.000128	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—multiple sclerosis	3.39e-05	0.000127	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	3.39e-05	0.000314	CbGpPWpGaD
Tacrolimus—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.37e-05	0.000312	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Prednisone—multiple sclerosis	3.37e-05	0.000126	CcSEcCtD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	3.36e-05	0.000311	CbGpPWpGaD
Tacrolimus—Dyspepsia—Methotrexate—multiple sclerosis	3.36e-05	0.000126	CcSEcCtD
Tacrolimus—MTOR—Immune System—TNFAIP3—multiple sclerosis	3.36e-05	0.000311	CbGpPWpGaD
Tacrolimus—Vomiting—Dexamethasone—multiple sclerosis	3.33e-05	0.000125	CcSEcCtD
Tacrolimus—Vomiting—Betamethasone—multiple sclerosis	3.33e-05	0.000125	CcSEcCtD
Tacrolimus—PPP3CA—Signaling by GPCR—TYK2—multiple sclerosis	3.33e-05	0.000308	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CD80—multiple sclerosis	3.33e-05	0.000308	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—MAPK1—multiple sclerosis	3.33e-05	0.000308	CbGpPWpGaD
Tacrolimus—Decreased appetite—Methotrexate—multiple sclerosis	3.32e-05	0.000125	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—HLA-B—multiple sclerosis	3.32e-05	0.000307	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MAPK1—multiple sclerosis	3.31e-05	0.000306	CbGpPWpGaD
Tacrolimus—Rash—Dexamethasone—multiple sclerosis	3.31e-05	0.000124	CcSEcCtD
Tacrolimus—Rash—Betamethasone—multiple sclerosis	3.31e-05	0.000124	CcSEcCtD
Tacrolimus—Dermatitis—Betamethasone—multiple sclerosis	3.3e-05	0.000124	CcSEcCtD
Tacrolimus—Dermatitis—Dexamethasone—multiple sclerosis	3.3e-05	0.000124	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.3e-05	0.000124	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—IL6—multiple sclerosis	3.29e-05	0.000305	CbGpPWpGaD
Tacrolimus—Fatigue—Methotrexate—multiple sclerosis	3.29e-05	0.000124	CcSEcCtD
Tacrolimus—Headache—Dexamethasone—multiple sclerosis	3.29e-05	0.000123	CcSEcCtD
Tacrolimus—Headache—Betamethasone—multiple sclerosis	3.29e-05	0.000123	CcSEcCtD
Tacrolimus—Asthenia—Prednisone—multiple sclerosis	3.28e-05	0.000123	CcSEcCtD
Tacrolimus—Pain—Methotrexate—multiple sclerosis	3.26e-05	0.000123	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—GPR65—multiple sclerosis	3.26e-05	0.000301	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—IL6—multiple sclerosis	3.24e-05	0.0003	CbGpPWpGaD
Tacrolimus—Pruritus—Prednisone—multiple sclerosis	3.23e-05	0.000121	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—CD86—multiple sclerosis	3.2e-05	0.000296	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CNR1—multiple sclerosis	3.15e-05	0.000291	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCL5—multiple sclerosis	3.15e-05	0.000291	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Methotrexate—multiple sclerosis	3.15e-05	0.000118	CcSEcCtD
Tacrolimus—FKBP1A—Disease—CCR5—multiple sclerosis	3.14e-05	0.000291	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SRM—multiple sclerosis	3.14e-05	0.000291	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.13e-05	0.000289	CbGpPWpGaD
Tacrolimus—Diarrhoea—Prednisone—multiple sclerosis	3.13e-05	0.000117	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—multiple sclerosis	3.12e-05	0.000117	CcSEcCtD
Tacrolimus—Nausea—Dexamethasone—multiple sclerosis	3.12e-05	0.000117	CcSEcCtD
Tacrolimus—Nausea—Betamethasone—multiple sclerosis	3.12e-05	0.000117	CcSEcCtD
Tacrolimus—ALB—Folate Metabolism—IL6—multiple sclerosis	3.1e-05	0.000287	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—IL6—multiple sclerosis	3.1e-05	0.000287	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—IL6—multiple sclerosis	3.08e-05	0.000285	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—RRM1—multiple sclerosis	3.07e-05	0.000284	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-A—multiple sclerosis	3.07e-05	0.000284	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.07e-05	0.000284	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—IL6—multiple sclerosis	3.07e-05	0.000284	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HLA-A—multiple sclerosis	3.06e-05	0.000283	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	3.06e-05	0.000283	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—IL6—multiple sclerosis	3.05e-05	0.000282	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—TYK2—multiple sclerosis	3.04e-05	0.000282	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.04e-05	0.000282	CbGpPWpGaD
Tacrolimus—Urticaria—Methotrexate—multiple sclerosis	3.03e-05	0.000114	CcSEcCtD
Tacrolimus—MTOR—Immune System—CD28—multiple sclerosis	3.02e-05	0.00028	CbGpPWpGaD
Tacrolimus—Dizziness—Prednisone—multiple sclerosis	3.02e-05	0.000113	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—multiple sclerosis	3.02e-05	0.000113	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—multiple sclerosis	3.02e-05	0.000113	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—STAT3—multiple sclerosis	2.98e-05	0.000276	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCR1—multiple sclerosis	2.98e-05	0.000276	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL13—multiple sclerosis	2.98e-05	0.000276	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CCR2—multiple sclerosis	2.97e-05	0.000275	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTPRC—multiple sclerosis	2.97e-05	0.000275	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	2.93e-05	0.000271	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	2.93e-05	0.000271	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—TLR4—multiple sclerosis	2.93e-05	0.000271	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TNF—multiple sclerosis	2.92e-05	0.00027	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SPP1—multiple sclerosis	2.91e-05	0.00027	CbGpPWpGaD
Tacrolimus—Vomiting—Prednisone—multiple sclerosis	2.9e-05	0.000109	CcSEcCtD
Tacrolimus—Rash—Prednisone—multiple sclerosis	2.88e-05	0.000108	CcSEcCtD
Tacrolimus—Dermatitis—Prednisone—multiple sclerosis	2.88e-05	0.000108	CcSEcCtD
Tacrolimus—MTOR—DAP12 interactions—IL6—multiple sclerosis	2.87e-05	0.000266	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	2.87e-05	0.000266	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—IL6—multiple sclerosis	2.87e-05	0.000266	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-DPB1—multiple sclerosis	2.87e-05	0.000266	CbGpPWpGaD
Tacrolimus—Headache—Prednisone—multiple sclerosis	2.86e-05	0.000107	CcSEcCtD
Tacrolimus—FKBP1A—Disease—APOE—multiple sclerosis	2.86e-05	0.000264	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IFNG—multiple sclerosis	2.85e-05	0.000264	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—IL6—multiple sclerosis	2.84e-05	0.000263	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCR5—multiple sclerosis	2.83e-05	0.000262	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL10—multiple sclerosis	2.83e-05	0.000262	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—IL6—multiple sclerosis	2.82e-05	0.000261	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Methotrexate—multiple sclerosis	2.81e-05	0.000106	CcSEcCtD
Tacrolimus—PPP3CA—Disease—TYK2—multiple sclerosis	2.81e-05	0.00026	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HLA-DRB1—multiple sclerosis	2.81e-05	0.00026	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—IL6—multiple sclerosis	2.81e-05	0.00026	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—STAT3—multiple sclerosis	2.8e-05	0.000259	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2RA—multiple sclerosis	2.79e-05	0.000259	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD28—multiple sclerosis	2.79e-05	0.000258	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL2—multiple sclerosis	2.77e-05	0.000257	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD40—multiple sclerosis	2.76e-05	0.000255	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ITGA4—multiple sclerosis	2.76e-05	0.000255	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD4—multiple sclerosis	2.75e-05	0.000255	CbGpPWpGaD
Tacrolimus—Asthenia—Methotrexate—multiple sclerosis	2.74e-05	0.000103	CcSEcCtD
Tacrolimus—MTOR—Immune System—IFNB1—multiple sclerosis	2.74e-05	0.000254	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CTLA4—multiple sclerosis	2.72e-05	0.000252	CbGpPWpGaD
Tacrolimus—Nausea—Prednisone—multiple sclerosis	2.71e-05	0.000102	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—MAPK1—multiple sclerosis	2.71e-05	0.000251	CbGpPWpGaD
Tacrolimus—Pruritus—Methotrexate—multiple sclerosis	2.7e-05	0.000101	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—CD80—multiple sclerosis	2.7e-05	0.00025	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ICAM1—multiple sclerosis	2.69e-05	0.000249	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.69e-05	0.000249	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GPC5—multiple sclerosis	2.68e-05	0.000248	CbGpPWpGaD
Tacrolimus—Diarrhoea—Methotrexate—multiple sclerosis	2.61e-05	9.81e-05	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—CD80—multiple sclerosis	2.59e-05	0.00024	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—ITGA4—multiple sclerosis	2.58e-05	0.000239	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CD80—multiple sclerosis	2.58e-05	0.000239	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—APOE—multiple sclerosis	2.58e-05	0.000239	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IFNB1—multiple sclerosis	2.57e-05	0.000238	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—IL6—multiple sclerosis	2.56e-05	0.000237	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—MAPK1—multiple sclerosis	2.54e-05	0.000236	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL1B—multiple sclerosis	2.54e-05	0.000235	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CD4—multiple sclerosis	2.54e-05	0.000235	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	2.54e-05	0.000235	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL2—multiple sclerosis	2.53e-05	0.000235	CbGpPWpGaD
Tacrolimus—Dizziness—Methotrexate—multiple sclerosis	2.52e-05	9.48e-05	CcSEcCtD
Tacrolimus—ALB—Metabolism—CYP27B1—multiple sclerosis	2.52e-05	0.000234	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP24A1—multiple sclerosis	2.52e-05	0.000234	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CD86—multiple sclerosis	2.48e-05	0.000229	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.47e-05	0.000228	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	2.47e-05	0.000228	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCL5—multiple sclerosis	2.44e-05	0.000226	CbGpPWpGaD
Tacrolimus—Vomiting—Methotrexate—multiple sclerosis	2.43e-05	9.12e-05	CcSEcCtD
Tacrolimus—Rash—Methotrexate—multiple sclerosis	2.41e-05	9.04e-05	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—multiple sclerosis	2.4e-05	9.03e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—VCAM1—multiple sclerosis	2.4e-05	0.000222	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-DQA1—multiple sclerosis	2.39e-05	0.000222	CbGpPWpGaD
Tacrolimus—Headache—Methotrexate—multiple sclerosis	2.39e-05	8.98e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—CD80—multiple sclerosis	2.33e-05	0.000216	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GPC5—multiple sclerosis	2.31e-05	0.000214	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—TYK2—multiple sclerosis	2.28e-05	0.000211	CbGpPWpGaD
Tacrolimus—Nausea—Methotrexate—multiple sclerosis	2.27e-05	8.52e-05	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—SPP1—multiple sclerosis	2.26e-05	0.000209	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-DQB1—multiple sclerosis	2.24e-05	0.000207	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—RRM1—multiple sclerosis	2.22e-05	0.000206	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—POMC—multiple sclerosis	2.22e-05	0.000205	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.21e-05	0.000205	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.21e-05	0.000205	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCR5—multiple sclerosis	2.2e-05	0.000203	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TYK2—multiple sclerosis	2.18e-05	0.000202	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCL2—multiple sclerosis	2.17e-05	0.000201	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2RA—multiple sclerosis	2.17e-05	0.000201	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD86—multiple sclerosis	2.16e-05	0.0002	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—STAT3—multiple sclerosis	2.13e-05	0.000197	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL3—multiple sclerosis	2.12e-05	0.000196	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—MAPK1—multiple sclerosis	2.12e-05	0.000196	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD40LG—multiple sclerosis	2.11e-05	0.000196	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD8A—multiple sclerosis	2.09e-05	0.000194	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—IL6—multiple sclerosis	2.08e-05	0.000193	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CD4—multiple sclerosis	2.06e-05	0.000191	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTGER4—multiple sclerosis	2.04e-05	0.000189	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GPC5—multiple sclerosis	2.02e-05	0.000187	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-B—multiple sclerosis	2.01e-05	0.000186	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PGR—multiple sclerosis	2.01e-05	0.000186	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	2.01e-05	0.000186	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—APOE—multiple sclerosis	2e-05	0.000185	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD86—multiple sclerosis	1.99e-05	0.000184	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD4—multiple sclerosis	1.98e-05	0.000183	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCR3—multiple sclerosis	1.97e-05	0.000183	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CD4—multiple sclerosis	1.97e-05	0.000182	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TYK2—multiple sclerosis	1.97e-05	0.000182	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—STAT3—multiple sclerosis	1.97e-05	0.000182	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—IL6—multiple sclerosis	1.95e-05	0.000181	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CD28—multiple sclerosis	1.95e-05	0.000181	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—MAPK1—multiple sclerosis	1.94e-05	0.000179	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SRM—multiple sclerosis	1.93e-05	0.000179	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCR2—multiple sclerosis	1.92e-05	0.000178	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—RRM1—multiple sclerosis	1.91e-05	0.000177	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2RA—multiple sclerosis	1.88e-05	0.000174	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-A—multiple sclerosis	1.86e-05	0.000173	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MYC—multiple sclerosis	1.83e-05	0.000169	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—TGFB1—multiple sclerosis	1.82e-05	0.000169	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CD80—multiple sclerosis	1.81e-05	0.000167	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.79e-05	0.000166	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MAPK1—multiple sclerosis	1.79e-05	0.000166	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CNR1—multiple sclerosis	1.77e-05	0.000164	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2RA—multiple sclerosis	1.77e-05	0.000163	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CCR5—multiple sclerosis	1.77e-05	0.000163	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.76e-05	0.000163	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HLA-A—multiple sclerosis	1.72e-05	0.000159	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—POMC—multiple sclerosis	1.72e-05	0.000159	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TLR4—multiple sclerosis	1.7e-05	0.000158	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-DRB1—multiple sclerosis	1.7e-05	0.000158	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCL2—multiple sclerosis	1.68e-05	0.000156	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—RRM1—multiple sclerosis	1.68e-05	0.000155	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2—multiple sclerosis	1.64e-05	0.000152	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ICAM1—multiple sclerosis	1.63e-05	0.000151	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL6—multiple sclerosis	1.63e-05	0.000151	CbGpPWpGaD
Tacrolimus—MTOR—Disease—APOE—multiple sclerosis	1.61e-05	0.000149	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL10—multiple sclerosis	1.59e-05	0.000148	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD80—multiple sclerosis	1.57e-05	0.000146	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.57e-05	0.000145	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MMP9—multiple sclerosis	1.55e-05	0.000144	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.55e-05	0.000143	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.54e-05	0.000143	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.54e-05	0.000142	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TYK2—multiple sclerosis	1.53e-05	0.000141	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—STAT3—multiple sclerosis	1.53e-05	0.000141	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.51e-05	0.00014	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL6—multiple sclerosis	1.49e-05	0.000138	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.48e-05	0.000137	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD80—multiple sclerosis	1.45e-05	0.000134	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—MAPK1—multiple sclerosis	1.45e-05	0.000134	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.44e-05	0.000133	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MYC—multiple sclerosis	1.42e-05	0.000131	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TGFB1—multiple sclerosis	1.41e-05	0.000131	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CD86—multiple sclerosis	1.39e-05	0.000129	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MAPK1—multiple sclerosis	1.39e-05	0.000128	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—STAT3—multiple sclerosis	1.38e-05	0.000128	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—IL6—multiple sclerosis	1.37e-05	0.000127	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL5—multiple sclerosis	1.37e-05	0.000127	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.36e-05	0.000126	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.36e-05	0.000126	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TYK2—multiple sclerosis	1.33e-05	0.000123	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—multiple sclerosis	1.28e-05	0.000119	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TGFB1—multiple sclerosis	1.28e-05	0.000118	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.28e-05	0.000118	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.27e-05	0.000118	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SPP1—multiple sclerosis	1.27e-05	0.000118	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—multiple sclerosis	1.27e-05	0.000118	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MAPK1—multiple sclerosis	1.25e-05	0.000116	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.25e-05	0.000115	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNG—multiple sclerosis	1.24e-05	0.000115	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCR5—multiple sclerosis	1.24e-05	0.000114	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TYK2—multiple sclerosis	1.23e-05	0.000113	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2RA—multiple sclerosis	1.22e-05	0.000113	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—multiple sclerosis	1.2e-05	0.000111	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD4—multiple sclerosis	1.2e-05	0.000111	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APOE—multiple sclerosis	1.12e-05	0.000104	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—multiple sclerosis	1.11e-05	0.000103	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1B—multiple sclerosis	1.11e-05	0.000103	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD4—multiple sclerosis	1.11e-05	0.000103	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—multiple sclerosis	1.1e-05	0.000102	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—BCHE—multiple sclerosis	1.1e-05	0.000102	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—multiple sclerosis	1.07e-05	9.89e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—multiple sclerosis	1.07e-05	9.87e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APOE—multiple sclerosis	1.06e-05	9.83e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—multiple sclerosis	1.04e-05	9.58e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.03e-05	9.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CD80—multiple sclerosis	1.02e-05	9.41e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—multiple sclerosis	9.93e-06	9.19e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—multiple sclerosis	9.91e-06	9.17e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAPK1—multiple sclerosis	9.72e-06	8.99e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.68e-06	8.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—POMC—multiple sclerosis	9.66e-06	8.94e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—multiple sclerosis	9.63e-06	8.91e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—BCHE—multiple sclerosis	9.63e-06	8.91e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL2—multiple sclerosis	9.45e-06	8.75e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—multiple sclerosis	9.3e-06	8.61e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—POMC—multiple sclerosis	9.12e-06	8.44e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TYK2—multiple sclerosis	8.58e-06	7.95e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—multiple sclerosis	8.58e-06	7.95e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MAPK1—multiple sclerosis	8.45e-06	7.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ALB—multiple sclerosis	8.31e-06	7.7e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—multiple sclerosis	8.08e-06	7.48e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—multiple sclerosis	7.98e-06	7.38e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—multiple sclerosis	7.96e-06	7.37e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—MAPK1—multiple sclerosis	7.92e-06	7.33e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MAPK1—multiple sclerosis	7.8e-06	7.22e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOE—multiple sclerosis	7.67e-06	7.1e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—multiple sclerosis	7.47e-06	6.91e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—multiple sclerosis	7.14e-06	6.61e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—multiple sclerosis	6.76e-06	6.26e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOE—multiple sclerosis	6.61e-06	6.12e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—POMC—multiple sclerosis	6.59e-06	6.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—multiple sclerosis	6.49e-06	6.01e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—multiple sclerosis	6.01e-06	5.56e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALB—multiple sclerosis	6.01e-06	5.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—multiple sclerosis	6e-06	5.55e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—BCHE—multiple sclerosis	5.93e-06	5.49e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOE—multiple sclerosis	5.79e-06	5.36e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—POMC—multiple sclerosis	5.68e-06	5.26e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—multiple sclerosis	5.59e-06	5.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—multiple sclerosis	5.57e-06	5.16e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAPK1—multiple sclerosis	5.46e-06	5.06e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—POMC—multiple sclerosis	4.97e-06	4.61e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALB—multiple sclerosis	4.54e-06	4.2e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—multiple sclerosis	4.2e-06	3.89e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOE—multiple sclerosis	3.57e-06	3.3e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—POMC—multiple sclerosis	3.06e-06	2.84e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALB—multiple sclerosis	2.79e-06	2.59e-05	CbGpPWpGaD
